Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
71.50    0.50 (0.70%)
Bid:
71.20
Ask:
74.00
Spread: 2.80 (3.933%)
Market Cap: £684.32m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

CFO Appointment

14 Nov 2023 07:00

RNS Number : 2912T
Dr. Martens PLC
14 November 2023
 

 

14 November 2023

Dr. Martens plc

CFO appointment

 

Dr. Martens plc ('the Company') announces that Giles Wilson has been appointed to the role of Chief Financial Officer (CFO). Giles will join Dr. Martens and take up his role in 2024, with the date to be confirmed and announced in due course.

Giles is an experienced CFO who joins Dr. Martens from William Grant & Sons Limited, one of the largest global spirits companies, owners of premium brands including Glenfiddich Scotch Whisky, The Balvenie Whisky and Hendrick's Gin. Prior to this, Giles was at John Menzies plc as CFO (2016-20), and then subsequently became CEO (2019-20). Giles qualified as a chartered accountant with PwC and previously held a senior role at Commercial Estates Group.

Paul Mason, Chair, said "Following a rigorous selection process, we are delighted to appoint Giles as CFO. He is a very capable finance leader with extensive experience in a number of sectors and, most recently, his time in the branded spirits industry has given him a good grounding in global brands and wholesale distribution management. His knowledge of the public markets will be a valuable asset to the team as Dr. Martens continues its growth in the listed environment. I look forward to him joining the Board."

Kenny Wilson, CEO, said "I am thrilled that Giles will be joining the leadership team and the Board. He brings a range of complementary skills and past experience that is highly relevant to our brand-first strategy. I am looking forward to working with him on the next phase of Dr. Martens' journey to become a £2billion revenue footwear brand."

Giles Wilson said "Dr. Martens is an iconic brand I have long admired, and I have been impressed by the passion and ambition within the business. I am excited to be joining at such an important stage in the Company's growth and I am looking forward to working with Kenny and the team to drive the strategy forward."

Jon Mortimore, who is retiring from the Company as previously announced, has agreed to stay with the business until the end of the financial year.

There are no further disclosures required in respect of this appointment pursuant to Listing Rule 9.6.13.

 

Enquiries

Investors and analysts

Bethany Barnes, Director of Investor Relations Bethany.Barnes@drmartens.com +44 7825 187465

Beth Callum, Senior Investor Relations Analyst Beth.Callum@drmartens.com +44 203 995 2644

 

Press

H/Advisors Maitland +44 207 379 5151

Clinton Manning +44 7711 972662

 

Gill Hammond, Director of Communications +44 7384 214248

 

 

Notes

Remuneration Arrangements

Giles Wilson's remuneration arrangements have been set in accordance with the Directors' Remuneration Policy detailed in the FY23 Annual Report. Further details will be set out in the Directors' Remuneration Report for FY24.

 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DM's" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOABJBRTMTBBBJJ
Date   Source Headline
31st Jan 20224:23 pmRNSDirector/PDMR Shareholding
27th Jan 20227:00 amRNSTrading Statement
11th Jan 20224:11 pmRNSDirector/PDMR Shareholding
10th Jan 20225:15 pmRNSHolding(s) in Company
6th Jan 20225:30 pmRNSDr Martens
6th Jan 20227:00 amRNSResult of Secondary Placing in Dr. Martens
5th Jan 20225:12 pmRNSProposed Secondary Placing in Dr. Martens plc
13th Dec 20211:33 pmRNSChange of Auditor
9th Dec 20217:00 amRNSHalf-year Report
1st Nov 202112:53 pmRNSTotal Voting Rights
30th Sep 20218:45 amRNSBlock Listing Application
15th Sep 20217:00 amRNSDirector/PDMR Shareholding
29th Jul 20211:06 pmRNSResult of AGM
29th Jul 20217:00 amRNSTrading Statement
12th Jul 202110:00 amRNSPrior year quarterly revenue figures
1st Jul 20219:00 amRNSAnnual Financial Report
25th Jun 202112:46 pmRNSHolding(s) in Company
23rd Jun 20216:19 pmRNSHolding(s) in Company
21st Jun 202110:39 amRNSDirector/PDMR Shareholding
18th Jun 20213:16 pmRNSHolding(s) in Company
17th Jun 20217:00 amRNSFinal Results
16th Jun 20215:40 pmRNSHolding(s) in Company
13th Apr 20217:00 amRNSAppointment of Joint Corporate Brokers
10th Feb 20219:00 amRNSDirector/PDMR Shareholding
9th Feb 20211:41 pmRNSHolding(s) in Company
5th Feb 202112:52 pmRNSHolding(s) in Company
5th Feb 20219:20 amRNSExercise of Over-allotment Option
4th Feb 20215:20 pmRNSHolding(s) in Company
3rd Feb 20218:00 amRNSTotal Voting Rights
3rd Feb 20218:00 amRNSAdmission to Trading on the London Stock Exchange
1st Feb 20214:53 pmRNSDirector/PDMR Shareholding
29th Jan 202111:18 amRNSStabilisation Notice
29th Jan 202110:48 amRNSApproval and Publication of Prospectus
29th Jan 20217:00 amRNSAnnouncement of Offer Price

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.